lenalidomide

Lenalidomide (CC-5013) is an immunomodulator with oral activity. Lenalidomide is a ligand for the ubiquitin E3 ligase cereblon (CRBN), which selectively ubiquitinates and degrades two lymphoid transcription factors, IKZF1 and IKZF3, via the CRBN-CRL4 ubiquitin ligase, and is commonly used in the synthesis of PROTAC products.

Lenalidomide-C4-NH2 hydrochloride is a Cereblon ligand derived from Lenalidomide. It serves as a recruiting agent for the CRBN protein. The compound, known as PROTAC (Compound 24), can be formed by linking Lenalidomide-C4-NH2 hydrochloride to the ligand for the protein. It exhibits inhibitory effects with IC50s of 0.98 nM and 13.7 nM against the growth of RS4;11 and MOLM-13 acute leukemia cell lines, respectively[1].

Lenalidomide-acetylene-C5-COOH (compound 43; Cereblon ligand-linker Conjugate) is a Lenalidomide-based Cereblon ligand that facilitates CRBN protein recruitment and can be linked to the protein's ligand via a linker, forming a PROTAC[1].

Lenalidomide-OH is an analog of Lenalidomide, a cereblon ligand for E3 ubiquitin ligase (CRBN), used for CRBN protein recruitment. It is able to attach to protein ligands using linkers to form PROTAC.

Lenalidomide-PEG3-iodine, an E3 ligase ligand-linker conjugate, consists of a cereblon-based Lenalidomide ligand and a 3-unit polyethylene glycol (PEG) linker. This compound is utilized in creating various proteolysis targeting chimeras (PROTACs), including the highly effective PROTAC BTK degrader SJF620, which has a degradation concentration 50 (DC50) of 7.9 nM[1].

Lenalidomide-propargyl-C2-amido-Ph-NH2 hydrochloride is a chemical compound comprising a cereblon (CRBN) ligand that functions as an E3 ubiquitin ligase, along with a linker. It is utilized to create the PROTAC MD-224[1].

Lenalidomide-propargyl-C2-NH2 hydrochloride is a compound that features a cereblon (CRBN) ligand for the E3 ubiquitin ligase, as well as a linker. It is utilized in the development of the PROTAC MD-224[1] system.

Lenalidomide hydrochloride (CC-5013 hydrochloride), a Thalidomide derivative, functions as molecular glue and serves as an orally active immunomodulator. As a ligand for the ubiquitin E3 ligase cereblon (CRBN), it facilitates the selective ubiquitination and degradation of the lymphoid transcription factors IKZF1 and IKZF3 through the CRBN-CRL4 ubiquitin ligase. Specifically, Lenalidomide hydrochloride inhibits the growth of mature B-cell lymphomas, including multiple myeloma, and promotes IL-2 release from T cells [1] [2].

Lenalidomide-5-Br is a Lenalidomide derivative that functions as a ligand for cereblon (CRBN), thereby facilitating the recruitment of CRBN protein. It can be conjugated to the protein ligand through a linker to generate a PROTAC molecule.

Lenalidomide-4-OH is a cereblon (CRBN) ligand derived from Lenalidomide, utilized in the recruitment of the CRBN protein. It can be conjugated to the protein ligand via a linker, facilitating the formation of PROTAC.

Lenalidomide-5-aminomethyl hydrochloride is a cereblon (CRBN) ligand derived from Lenalidomide. It serves as a ligand for the recruitment of the CRBN protein. When connected to the protein via a linker, Lenalidomide-5-aminomethyl hydrochloride forms a PROTAC.

Lenalidomide-C5-amido-Boc is a Cereblon ligand derived from Lenalidomide, and serves in the recruitment of CRBN protein. It can be effectively linked to the protein ligand through a linker, resulting in the formation of PROTAC.

Lenalidomide-I (Compound 72) is a derivative of the cereblon (CRBN) ligand, Lenalidomide, with affinity for E3 ubiquitin ligase. It facilitates the recruitment of CRBN protein. Lenalidomide-I can be utilized in PROTACs, such as the PROTAC BET degrader QCA570, by linking it to the targeted protein ligand through a linker.

Lenalidomide-6-F is a derivative of Lenalidomide that serves as a cereblon (CRBN) ligand facilitating the recruitment of CRBN protein. With the addition of a linker, Lenalidomide-6-F can be conjugated to the ligand for the protein, enabling the formation of PROTAC.

Lenalidomide-4-aminomethyl hydrochloride is a compound derived from Lenalidomide, serving as a cereblon (CRBN) ligand for the recruitment of CRBN protein. By connecting Lenalidomide-4-aminomethyl hydrochloride to the ligand via a linker, PROTAC formation can be facilitated.

Lenalidomide-4-aminomethyl is a CRBN ligand derived from Lenalidomide, which is utilized for the recruitment of CRBN protein. By linking Lenalidomide-4-aminomethyl to the ligand, a PROTAC can be formed.

Lenalidomide hemihydrate is a derivative of Thalidomide, an orally active immunomodulator that acts as a molecular gel. It is a ligand for the ubiquitin E3 ligase cereblon, which selectively ubiquitinates and degrades two lymphoid transcription factors, IKZF1 and IKZF3, via the CRBN-CRL4 ubiquitin ligase.

Lenalidomide-Br (Compound 41), a derivative of Lenalidomide, acts as a ligand for cereblon (CRBN) - an E3 ubiquitin ligase involved in protein recruitment. This compound can be conjugated to a protein ligand via a linker to create PROTACs, such as the PROTAC STAT3 degrader SD-36.

Lenalidomide-F serves as the E3 ligase ligand for LWY713. LWY713 is a PROTAC-based FLT3 degrader (DC50= 0.64 nM) that selectively induces the degradation of FLT3 through a cereblon and proteasome-dependent mechanism.

Lenalidomide-Glycolic acid is a conjugate of an E3 ligase ligand and a linker, used in the synthesis of the PROTAC-type FLT3 degrader LWY713.

Lenalidomide-hex-5-ynoic acid is a conjugate of an E3 ligase ligand and linker, utilized in the synthesis of PROTACs, such as PROTACcGAS degrader-1.

Lenalidomide-5-Br-amide-C2-Br is an E3 ligase ligand-linker conjugate [E3ligaseligand-linker conjugate] that can be used for the synthesis of PROTACDDR1degrader-1.

Lenalidomide 5'-piperazine-7'-methoxy is a functional ligand for brain nuclei used in PROTAC research; it includes an E3 ligand with a terminal piperazine to create protein degraders featuring a rigid linker.

Lenalidomide-C5-NH2 hydrochloride is a Lenalidomide-based Cereblon ligand that recruits CRBN proteins. This compound can be connected via a linker to a target protein ligand, forming PROTAC molecules, such as the PROTAC degrader for MDM2.